tirzepatide nash phase 3 in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon? tirzepatide nash phase 3 FDA

Ivy Rx's microdose GLP-1 injections program is medically evaluated, provider-supervised, and structured to help you participate in GLP-1 therapy without being derailed by potential side effects

Den Boer ML, Harms DO, Pieters R, et al

When you lose weight through any method (surgery, medication, or lifestyle), your body reduces metabolic rate to defend against further weight loss

Their glucose-dependent mechanism limits the risk for hypoglycemia, and they are associated with weight loss

A qualified healthcare provider should evaluate fatigue in context of weight loss rate, nutritional intake, baseline biomarkers (hemoglobin, B12, folate, iron), and symptom trajectory

Goal: fat loss with maximum muscle preservation One concern with aggressive weight loss is lean mass loss